Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026)
Aytu Biopharma (AYTU) reported Return on Capital Employed of 17.99% for Q1 2026, down 1299.0% year-over-year from 1.5% in Q1 2025, and down 178.2% quarter-over-quarter from 6.47% in Q4 2025.
Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 16 years of Return on Capital Employed data on file, last reported at 17.99% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 17.99%, down 1299.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.99% (down 1299.0% YoY), and the FY2025 annual result was 4.99%, down 254.0% from the prior year.
- Return on Capital Employed retreated to 17.99% in Q1 2026 per AYTU's latest filing, from 6.47% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 89.24% in Q1 2023 and troughed at 100.45% in Q1 2022.
- A 5-year average of 2.78% and a median of 4.74% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 18969 bps in 2023, then sank 5833 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 9.81% in 2022, then advanced by 11 bps to 10.86% in 2023, then slumped by 215 bps to 12.49% in 2024, then jumped by 48 bps to 6.47% in 2025, then slumped by 178 bps to 17.99% in 2026.
- Business Quant data shows AYTU's Return on Capital Employed at 17.99% in Q1 2026, 6.47% in Q4 2025, and 5.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | -17.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.99% |
| Dec 31, 2025 | -6.47% |
| Sep 30, 2025 | -5.92% |
| Jun 30, 2025 | -4.74% |
| Mar 31, 2025 | -5.00% |
| Dec 31, 2024 | -12.49% |
| Sep 30, 2024 | -2.97% |
| Jun 30, 2024 | -2.60% |
| Mar 31, 2024 | 30.92% |
| Dec 31, 2023 | 10.86% |
| Sep 30, 2023 | -3.81% |
| Jun 30, 2023 | -4.92% |
| Mar 31, 2023 | 89.24% |
| Dec 31, 2022 | 9.81% |
| Sep 30, 2022 | 4.65% |
| Jun 30, 2022 | -25.46% |
| Mar 31, 2022 | -100.45% |
| Dec 31, 2021 | -54.82% |
| Sep 30, 2021 | -40.96% |
| Dec 31, 2020 | -16.04% |